Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

6.450 +0.115 (+1.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,391,448
Open 6.470
Bid (Size) 6.420 (1)
Ask (Size) 6.610 (7)
Prev. Close 6.335
Today's Range 6.430 - 6.765
52wk Range 5.033 - 12.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits

Performance

YTD
-14.46%
-14.46%
1 Month
-21.15%
-21.15%
3 Month
-11.76%
-11.76%
6 Month
+7.68%
+7.68%
1 Year
-17.94%
-17.94%

More News

Read More
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Present at Leerink’s Global Healthcare Conference 2025
From Mind Medicine Inc.
Via Business Wire
New Study Shows Ibogaine Can Be Made Without Using Plant Matter
Via Investor Brand Network
Why Mind Medicine Stock Is Skyrocketing Today
Via The Motley Fool
Why Mind Medicine Stock Is Soaring Today
Via The Motley Fool
Earnings Scheduled For March 6, 2025
Via Benzinga
Warren Buffett's State of the Market
Via The Motley Fool
Groups of Military Veterans Urge Congress to Expedite Research on Psychedelics
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
From Mind Medicine Inc.
Via Business Wire
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Via Stocktwits
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
Via Investor's Business Daily
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Mind Medicine Inc.
Via Business Wire
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
Via Stocktwits
This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
MindMed to Be Added to the Nasdaq Biotechnology Index
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
From Mind Medicine
Via Business Wire
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
From Mind Medicine Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
Via The Motley Fool
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
From Mind Medicine (MindMed) Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.